The Asian Scientist 100
Emi Ito
Institution
Osaka University
Country
Japan
Field
Life Sciences
Ito was awarded the 2023 JSPS Ikushi Prize by the Japan Society for the Promotion of Science for her research on unraveling the role of host-derived metabolites in the development of innate-type T cells.
(Photo: Osaka University)
AWARDS
- 2023 JSPS Ikushi Prize
Related articles
Feeder-Free Stem Cells With CCL2
Stem cells are now one step closer to the clinic, thanks to the development of feeder-free culture methods using the chemokine CCL2.
Optimising The Person-Job Fit
How can employers recruit the most suitable candidates, and how can an individual choose the best career? SMU Assistant Professor Serena Wee’s research points to a way of reaching an optimal solution.
Scientists & Journalists Call For Better Communication
Scientists and science journalists shared ideas for overcoming the barriers to better science communication in India at a two day seminar in Bangalore.
Bridging The ASEAN Research Gap
Research and innovation in ASEAN has not kept pace with economic growth the region has enjoyed, writes Crispin Maslog.
Algae Able To Switch Quantum Coherence On & Off
Scientists have found that the quantum coherence of light harvesting systems in single-celled algae is controlled by a single amino acid switch.
WIPO’s Patent Pool Yet To Deliver New Drug Candidates
Although the UN World Intellectual Property Organization (WIPO) project to facilitate patent sharing has been running for three years, no new drugs are currently in development.
HSV Babies Disproportionately Born To Young Mums
A 15 year longitudinal population study reveals that babies born with HSV infection are four times more likely to have young mothers below 20 years of age.
Indian Plant Compound Could Play Role In Cancer Cell Death
Gedunin, an extract of the Indian neem tree that has been used for centuries in Asia as a natural remedy to treat inflammation, fever, and malaria, may also be used to help kill cancer cells.
Blocking STAT5 To Fight Leukemia
Blocking STAT5 in conjunction with standard tyrosine kinase inhibitor drugs could be a powerful one-two punch that kills leukemic cells.